erenumab
-
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention
Jun 24, 2017News Hour: Novartis announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for AMG 334 (erenumab) for the prevention of a migraine. Erenumab is an anti-CGRP monoclonal antibody developed to prevent a...
